Table 3. HRs* (95% CIs) of breast cancer by ER and PR status in relation to quartiles of B vitamin intake in ORDET women.
| ER+ | ER- | PR+ | PR- | |||||
|---|---|---|---|---|---|---|---|---|
| Cases/person-year | Multivariable HR (95% CI)* | Cases/person-year | Multivariable HR (95% CI) | Cases/person-year | Multivariable HR (95% CI) | Cases/person-year | Multivariable HR (95% CI) | |
| Thiamine | ||||||||
| I | 90/34246 | 1 | 25/33593 | 1 | 71/34039 | 1 | 43/33788 | 1 |
| II | 72/34283 | 0.80 (0.57–1.12) | 17/33777 | 0.56 (0.29–1.08) | 54/34085 | 0.76 (0.51–1.11) | 35/33973 | 0.72 (0.44–1.18) |
| III | 61/34083 | 0.68 (0.45–1.03) | 16/33632 | 0.46 (0.22–0.98) | 53/33995 | 0.74 (0.47–1.16) | 25/33732 | 0.48 (0.26–0.89) |
| IV | 59/34487 | 0.65 (0.37–1.13) | 24/34057 | 0.51 (0.20–1.33) | 58/34426 | 0.80 (0.44–1.44) | 23/34102 | 0.37 (0.16–0.88) |
| P trend** | 0.087 | 0.118 | 0.388 | 0.012 | ||||
| Continuous# | 0.85 (0.65–1.11) | 0.88 (0.55–1.41) | 0.89 (0.67–1.18) | 0.75 (0.50–1.13) | ||||
| P for heterogeneity## | 0.870 | 0.516 | ||||||
| Riboflavin | ||||||||
| I | 105/34534 | 1 | 28/33742 | 1 | 87/34318 | 1 | 46/33959 | 1 |
| II | 66/34140 | 0.57 (0.41–0.80) | 13/33629 | 0.41 (0.21–0.80) | 51/33988 | 0.52 (0.36–0.74) | 26/33770 | 0.55 (0.33–0.91) |
| III | 58/34184 | 0.49 (0.34–0.71) | 17/33811 | 0.47 (0.24–0.92) | 49/34063 | 0.45 (0.30–0.68) | 27/33938 | 0.58 (0.33–1.01) |
| IV | 53/34241 | 0.40 (0.25–0.65) | 24/33876 | 0.53 (0.24–1.19) | 49/34177 | 0.38 (0.23–0.63) | 27/33928 | 0.57 (0.29–1.14) |
| P trend | <0.001 | 0.129 | <0.001 | 0.103 | ||||
| Continuous# | 0.77 (0.63–0.94) | 0.89 (0.63–1.25) | 0.72 (0.58–0.89) | 0.94 (0.71–1.25) | ||||
| P for heterogeneity## | 0.472 | 0.130 | ||||||
| Niacin | ||||||||
| I | 75/33964 | 1 | 24/33457 | 1 | 56/33752 | 1 | 42/33658 | 1 |
| II | 80/34387 | 1.10 (0.79–1.54) | 20/33812 | 0.74 (0.40–1.38) | 69/34261 | 1.23 (0.85–1.79) | 32/33949 | 0.76 (0.47–1.23) |
| III | 70/34318 | 1.04 (0.71–1.52) | 14/33778 | 0.46 (0.22–0.95) | 57/34177 | 1.06 (0.69–1.62) | 27/33918 | 0.64 (0.37–1.13) |
| IV | 57/34429 | 0.93 (0.57–1.50) | 24/34012 | 0.64 (0.28–1.44) | 54/34356 | 1.04 (0.62–1.75) | 25/34070 | 0.60 (0.30–1.22) |
| P trend | 0.761 | 0.155 | 0.958 | 0.121 | ||||
| Continuous# | 0.89 (0.73–1.08) | 0.80 (0.56–1.13) | 0.92 (0.75–1.14) | 0.75 (0.55–1.02) | ||||
| P for heterogeneity## | 0.601 | 0.262 | ||||||
| Vitamin B6 | ||||||||
| I | 88/34211 | 1 | 25/33575 | 1 | 67/33988 | 1 | 44/33781 | 1 |
| II | 76/34191 | 0.84 (0.60–1.16) | 19/33633 | 0.65 (0.35–1.21) | 62/34030 | 0.88 (0.61–1.27) | 34/33806 | 0.72 (0.45–1.16) |
| III | 61/34270 | 0.67 (0.45–0.98) | 15/33829 | 0.45 (0.22–0.92) | 54/34179 | 0.74 (0.49–1.12) | 23/33925 | 0.47 (0.26–0.85) |
| IV | 57/34427 | 0.62 (0.38–1.01) | 23/34022 | 0.52 (0.23–1.20) | 53/34349 | 0.70 (0.41–1.18) | 25/34084 | 0.48 (0.23–0.98) |
| P trend | 0.030 | 0.073 | 0.133 | 0.016 | ||||
| Continuous# | 0.82 (0.66–1.00) | 0.63 (0.44–0.91) | 0.88 (0.71–1.10) | 0.58 (0.42–0.80) | ||||
| P for heterogeneity## | 0.240 | 0.031 | ||||||
| Folate | ||||||||
| I | 83/34188 | 1 | 23/33557 | 1 | 64/33982 | 1 | 41/33752 | 1 |
| II | 82/34353 | 0.98 (0.71–1.35) | 17/33745 | 0.66 (0.35–1.27) | 66/34175 | 0.98 (0.68–1.41) | 32/33917 | 0.80 (0.49–1.30) |
| III | 69/34415 | 0.81 (0.57–1.17) | 19/33941 | 0.68 (0.34–1.33) | 63/34326 | 0.90 (0.60–1.33) | 26/34042 | 0.66 (0.38–1.14) |
| IV | 48/34144 | 0.58 (0.36–0.91) | 23/33816 | 0.73 (0.34–1.60) | 43/34063 | 0.58 (0.35–0.96) | 27/33884 | 0.74 (0.39–1.41) |
| P trend | 0.018 | 0.467 | 0.049 | 0.254 | ||||
| Continuous# | 0.84 (0.70–1.00) | 0.98 (0.72–1.32) | 0.84 (0.69–1.01) | 0.93 (0.71–1.20) | ||||
| P for heterogeneity## | 0.378 | 0.534 | ||||||
* Adjusted for height, waist-hip-ratio, age at menarche, menopausal status, oral contraceptive use, parity, education, family history of breast cancer, energy intake, and alcohol intake.
** Tests for linear trend calculated by assigning an ordinal number to each quartile.
# HR of developing breast cancer per 1 SD increase in vitamin intake.
## Receptor positive vs. receptor negative (ER+ vs. ER-; PR+ vs. PR-).